EGFR and non-small cell lung carcinoma: The PAPILLON trial examined the addition of amivantamab, a bispecific antibody targeting EGFR and c-MET that can activate monocytes/macrophages and NK cells through its Fc domain, to chemotherapy in patients with NSCLC with EGFR exon 20 insertions [102].